title: Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
abstract: We showed previously that amifostine (WR 2721; Ethyol), a protector against carboplatin-induced toxicities, changed the pharmacokinetics of carboplatin in tumor-bearing nude mice. In the present study, the influence of amifostine on the pharmacokinetics of carboplatin was studied in patients when carboplatin was given in combination with three doses of amifostine, administered just before the carboplatin infusion and 2-4 h thereafter. Compared with a control group of patients who received carboplatin alone, the patients receiving the combination had a longer final half-life of ultrafilterable platinum species [5.0 h versus 3.5 h in patients with a normal creatinine clearance (Clcr > 80 ml/min); 5.6 h versus 4.2 h in those with an impaired renal function (50 < Clcr < 80 ml/min)]. This might be caused by an influence of amifostine on the renal clearance of carboplatin as suggested by a transient increase in serum creatinine levels 24 h after treatment in the patients receiving the combination (mean +/- SD: 34.1% +/- 17.2% versus -1.8% +/- 16.5% in patients treated with carboplatin alone). The impact of these changes on the area under the concentration-time curves of the ultrafilterable platinum species was hardly noticeable in patients with a normal renal function but led to a significant increase in patients with an impaired renal function (395 +/- 59 micromol/l.h versus 280 +/- 62 micromol/l.h in patients receiving carboplatin alone). The clinical relevance of this influence is unclear, although theoretically it may result in an increase in the efficacy of carboplatin, as has been observed in tumor-bearing nude mice.
authors.affiliation: University Hospital Vrije Universiteit, Department of Medical Oncology, BR 232, 1007 MB Amsterdam, The Neterthlands.
authors.forename: A E
authors.initials: AE
authors.lastname: Korst
authors.forename: M L
authors.initials: ML
authors.lastname: van der Sterre
authors.forename: C M
authors.initials: CM
authors.lastname: Eeltink
authors.forename: A M
authors.initials: AM
authors.lastname: Fichtinger-Schepman
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
authors.forename: W J
authors.initials: WJ
authors.lastname: van der Vijgh
mesh_terms: D004999:Amifostine / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D016190:Carboplatin / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D007668:Kidney / Q000187:drug effects; D007677:Kidney Function Tests; D008657:Metabolic Clearance Rate; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D004999:Amifostine